Published in Toxins (Basel) on July 01, 2010
Clostridium perfringens epsilon toxin: a malevolent molecule for animals and man? Toxins (Basel) (2013) 1.08
Identification of amino acids important for binding of Clostridium perfringens epsilon toxin to host cells and to HAVCR1. Biochemistry (2012) 0.92
Oligomerization of Clostridium perfringens epsilon toxin is dependent upon caveolins 1 and 2. PLoS One (2012) 0.84
The Myelin and Lymphocyte Protein MAL Is Required for Binding and Activity of Clostridium perfringens ε-Toxin. PLoS Pathog (2015) 0.84
Identification of novel compounds inhibiting chikungunya virus-induced cell death by high throughput screening of a kinase inhibitor library. PLoS Negl Trop Dis (2013) 0.82
Obstructing toxin pathways by targeted pore blockage. Chem Rev (2012) 0.80
Coenzyme depletion by members of the aerolysin family of pore-forming toxins leads to diminished ATP levels and cell death. Mol Biosyst (2012) 0.77
Inhibiting bacterial toxins by channel blockage. Pathog Dis (2015) 0.75
Inhibition of Clostridium perfringens epsilon toxin by β-cyclodextrin derivatives. Int J Pharm (2017) 0.75
A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen (1999) 32.67
Database resources of the National Center for Biotechnology Information. Nucleic Acids Res (2006) 18.85
Statistical practice in high-throughput screening data analysis. Nat Biotechnol (2006) 5.85
ChemBank: a small-molecule screening and cheminformatics resource database. Nucleic Acids Res (2007) 5.10
Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest (2002) 4.97
Bacterial toxins: a table of lethal amounts. Microbiol Rev (1982) 3.74
Improved statistical methods for hit selection in high-throughput screening. J Biomol Screen (2003) 3.15
Structure of the Aeromonas toxin proaerolysin in its water-soluble and membrane-channel states. Nature (1994) 2.18
Identification of small molecule inhibitors of anthrax lethal factor. Nat Struct Mol Biol (2003) 1.86
Clostridium perfringens epsilon-toxin shows structural similarity to the pore-forming toxin aerolysin. Nat Struct Mol Biol (2004) 1.55
Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg Infect Dis (2002) 1.51
Lambda-toxin of Clostridium perfringens activates the precursor of epsilon-toxin by releasing its N- and C-terminal peptides. Microbiol Immunol (1997) 1.48
Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl (2004) 1.44
Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem (2003) 1.43
Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J Biol Chem (2002) 1.36
Cleavage of a C-terminal peptide is essential for heptamerization of Clostridium perfringens epsilon-toxin in the synaptosomal membrane. J Biol Chem (2001) 1.34
Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun (2003) 1.34
Hit discovery and hit-to-lead approaches. Drug Discov Today (2006) 1.31
Clostridium perfringens epsilon-toxin acts on MDCK cells by forming a large membrane complex. J Bacteriol (1997) 1.26
Identification and characterization of small molecules that inhibit intracellular toxin transport. Infect Immun (2007) 1.23
Recovery of Clostridium welchii type D from man. Lancet (1955) 1.18
Clostridium perfringens epsilon toxin induces a rapid change of cell membrane permeability to ions and forms channels in artificial lipid bilayers. J Biol Chem (2001) 1.15
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. Drug Discov Today (2006) 1.14
Evaluation of a new cytotoxicity assay for Clostridium perfringens type D epsilon toxin. FEMS Microbiol Lett (1994) 1.06
Identification of small-molecule inhibitors of ricin and shiga toxin using a cell-based high-throughput screen. Toxicon (2010) 1.06
Clostridium perfringens epsilon toxin rapidly decreases membrane barrier permeability of polarized MDCK cells. Cell Microbiol (2003) 1.01
Clostridium welchii epsilon toxin in the intestinal contents of man. Lancet (1955) 0.99
Dominant-negative inhibitors of the Clostridium perfringens epsilon-toxin. J Biol Chem (2009) 0.99
Cross-inhibition between furin and lethal factor inhibitors. Biochem Biophys Res Commun (2004) 0.98
Effect of epsilon toxin-GFP on MDCK cells and renal tubules in vivo. J Histochem Cytochem (2004) 0.98
Binding of epsilon-toxin from Clostridium perfringens in the nervous system. Vet Microbiol (2008) 0.97
Assembly of Clostridium perfringens epsilon-toxin on MDCK cell membrane. J Nat Toxins (1998) 0.96
Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon-toxin. Infect Immun (2007) 0.95
HTS-Corrector: software for the statistical analysis and correction of experimental high-throughput screening data. Bioinformatics (2006) 0.95
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorg Med Chem (2009) 0.95
Accumulation of Clostridium perfringens epsilon-toxin in the mouse kidney and its possible biological significance. Infect Immun (2003) 0.94
Discovery of a small molecule that inhibits the interaction of anthrax edema factor with its cellular activator, calmodulin. Chem Biol (2004) 0.94
Development of monoclonal antibodies suitable for use in antigen quantification potency tests for clostridial veterinary vaccines. Dev Biol Stand (1999) 0.94
Evaluation of inhibitory potencies for compounds inhibiting P-glycoprotein but without maximum effects: f2 values. Drug Metab Dispos (2005) 0.89
Variability of serum antibody responses of goat kids to a commercial Clostridium perfringens epsilon toxoid vaccine. Vet Rec (1998) 0.89
Increased efficiency for performing colony formation assays in 96-well plates: novel applications to combination therapies and high-throughput screening. Biotechniques (2008) 0.89
Distribution of Clostridium perfringens epsilon toxin in the brains of acutely intoxicated mice and its effect upon glial cells. Toxicon (2007) 0.88
Isolation of Clostridium perfringens Type D from a Case of Gas Gangrene. J Bacteriol (1965) 0.83
Assessment of aspects of the toxicity of Clostridium perfringens epsilon-toxin using the MDCK cell line. Hum Exp Toxicol (1996) 0.83
The passive protection of lambs against Clostridium perfringens type D with semi-purified hyperimmune serum. Onderstepoort J Vet Res (1988) 0.77
Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. AIDS (2002) 0.77
Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface. PLoS Pathog (2011) 1.67
Crystal structure of the Helicobacter pylori vacuolating toxin p55 domain. Proc Natl Acad Sci U S A (2007) 1.46
Association of Helicobacter pylori vacuolating toxin (VacA) with lipid rafts. J Biol Chem (2002) 1.41
Protein-protein interactions among Helicobacter pylori cag proteins. J Bacteriol (2006) 1.14
Interactions between p-33 and p-55 domains of the Helicobacter pylori vacuolating cytotoxin (VacA). J Biol Chem (2003) 1.06
Helicobacter pylori VacA induces programmed necrosis in gastric epithelial cells. Infect Immun (2011) 1.05
Functional properties of the p33 and p55 domains of the Helicobacter pylori vacuolating cytotoxin. J Biol Chem (2005) 1.03
Gene-trap mutagenesis identifies mammalian genes contributing to intoxication by Clostridium perfringens ε-toxin. PLoS One (2011) 1.01
Dominant-negative inhibitors of the Clostridium perfringens epsilon-toxin. J Biol Chem (2009) 0.99
Analysis of cagA in Helicobacter pylori strains from Colombian populations with contrasting gastric cancer risk reveals a biomarker for disease severity. Cancer Epidemiol Biomarkers Prev (2011) 0.98
Identification of amino acids important for binding of Clostridium perfringens epsilon toxin to host cells and to HAVCR1. Biochemistry (2012) 0.92
Helicobacter pylori VacA subdomain required for intracellular toxin activity and assembly of functional oligomeric complexes. Infect Immun (2008) 0.92
Comparative genomic analysis of East Asian and non-Asian Helicobacter pylori strains identifies rapidly evolving genes. PLoS One (2013) 0.91
Role of connexin 43 in Helicobacter pylori VacA-induced cell death. Infect Immun (2013) 0.89
Helicobacter pylori HopQ outer membrane protein attenuates bacterial adherence to gastric epithelial cells. FEMS Microbiol Lett (2008) 0.89
Reconstitution of Helicobacter pylori VacA toxin from purified components. Biochemistry (2010) 0.87
The intermediate region of Helicobacter pylori VacA is a determinant of toxin potency in a Jurkat T cell assay. Infect Immun (2012) 0.86
Genome Sequences of Three hpAfrica2 Strains of Helicobacter pylori. Genome Announc (2013) 0.85
Oligomerization of Clostridium perfringens epsilon toxin is dependent upon caveolins 1 and 2. PLoS One (2012) 0.84
Analysis of a beta-helical region in the p55 domain of Helicobacter pylori vacuolating toxin. BMC Microbiol (2010) 0.81
Mapping of a domain required for protein-protein interactions and inhibitory activity of a Helicobacter pylori dominant-negative VacA mutant protein. Infect Immun (2006) 0.81
Coenzyme depletion by members of the aerolysin family of pore-forming toxins leads to diminished ATP levels and cell death. Mol Biosyst (2012) 0.77